Last reviewed · How we verify
Belimumab plus Early Vaccination
Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.
Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response. Used for Systemic lupus erythematosus (SLE) with early vaccination strategy.
At a glance
| Generic name | Belimumab plus Early Vaccination |
|---|---|
| Also known as | BENLYSTA™ |
| Sponsor | Human Genome Sciences Inc., a GSK Company |
| Drug class | BLyS inhibitor monoclonal antibody |
| Target | B-lymphocyte stimulator (BLyS) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Belimumab is a monoclonal antibody that binds to and neutralizes soluble B-lymphocyte stimulator (BLyS), a key cytokine that promotes B cell survival and differentiation. By reducing BLyS signaling, belimumab decreases pathogenic autoantibody-producing B cells. The combination with early vaccination aims to leverage the immunosuppressive window created by belimumab to promote tolerogenic responses and prevent disease flares.
Approved indications
- Systemic lupus erythematosus (SLE) with early vaccination strategy
Common side effects
- Infection
- Nasopharyngitis
- Bronchitis
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: